Recent Company News

• 04:24 AM ET Jun 10, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:42 AM ET Jun 11, 2026
  

  Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress (€2.72, 0.00)

• 05:17 PM ET May 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:21 AM ET Jun 10, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:54 AM ET Jun 10, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:25 AM ET Jun 10, 2026
  

  StreetAccount Summary - US Pre-market trading

• 04:39 PM ET Jun 09, 2026
  

  Cellectis Receives FDA RMAT designation for lasme-cel, allogeneic CAR-T therapy in trial for patients with r/r B-ALL (€2.51, 0.00)